Anteris Technologies Global Q2 2025 Earnings: Revenue Exceeds Estimates, EPS Falls Short

Anteris Technologies Global reported Q2 2025 earnings with net loss of $20.8m, a 11% increase from Q2 2024, and a loss per share of $0.58. Revenue exceeded analyst estimates by 63%, but EPS missed estimates by 2.5%. The company's shares are up 5.4% from a week ago.

Anteris Technologies Global Corp. (NASDAQ: AVR) reported its second-quarter 2025 earnings, showing a net loss of $20.8 million, an 11% increase from the same period last year. The loss per share was $0.58, while revenue exceeded analyst estimates by 63%, but earnings per share (EPS) missed estimates by 2.5%. Despite the financial setback, the company's shares are up 5.4% from a week ago.

The quarter saw significant progress in the clinical development of Anteris' DurAVR® THV system, with the successful implantation of the device in 130 patients, including a world-first double valve-in-valve replacement. Preparations for the global PARADIGM Trial are underway, with 79 sites qualified and key appointments made to the Board of Directors [1].

Financially, the company reported net operating cash outflows of $41 million, reflecting increased clinical and manufacturing activities, with $28.4 million in cash reserves as of June 30, 2025 [2]. The recent analyst rating on AVR stock is a Buy with a A$15.00 price target [1].

Anteris' focus on clinical development is evident in its R&D expenses, which totaled $16.3 million in Q2 2025. The company continues to build momentum with its DurAVR THV system, demonstrating consistent patient adoption with 21 new implants this quarter, bringing the total to 130 patients treated since development began [3].

However, the financial picture reveals significant investment required to support these clinical and regulatory activities. Operating cash outflows reached $41 million for the first half of 2025, with $28.4 million cash remaining as of June 30, 2025, indicating a potential runway into early 2026 at current burn rates. The company's strategic board appointments of David Roberts and Gregory Moss strengthen operational leadership and corporate governance capabilities, crucial for the company's transition to the pivotal trial phase [3].

The appointment of high-profile co-chairs Dr. Michael Reardon and Professor Stephan Windecker to the PARADIGM Trial adds valuable credibility and experience to the trial. The ongoing FDA engagement for Investigational Device Exemption approval represents the critical regulatory gating item before full trial initiation. The company's financial position requires close attention as it transitions to its pivotal trial phase [3].

Anteris Technologies Global Corp. is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. The company's primary focus remains the upcoming global PARADIGM Trial, with substantial infrastructure development including 79 qualified clinical sites across multiple countries [1].

References:
[1] https://www.tipranks.com/news/company-announcements/anteris-technologies-advances-duravr-thv-development-in-q2-2025
[2] https://seekingalpha.com/news/4483571-anteris-technologies-reports-q2-results
[3] https://www.stocktitan.net/news/AVR/anteris-announces-results-for-the-second-quarter-of-ds5664ib6h0x.html